NYSE:VAR - Varian Medical Systems Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $177.70
  • Forecasted Upside: 0.36 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$177.07
+0.30 (1.20%)
Get New Varian Medical Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VAR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VAR

Analyst Price Target is $177.70
▲ +0.36% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Varian Medical Systems in the last 3 months. The average price target is $177.70, with a high forecast of $178.00 and a low forecast of $177.50. The average price target represents a 0.36% upside from the last price of $177.07.

This chart shows the closing price for VAR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in Varian Medical Systems. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 3 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 3 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 3 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 3 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 1 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 1 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 1 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021UBS GroupDowngradeBuy ➝ In-LineLow
2/23/2021UBS GroupDowngradeBuy ➝ In-LineLow
12/31/2020UBS GroupDowngradeIn-LineN/A
12/14/2020UBS GroupDowngradeIn-LineLow
12/7/2020UBS GroupDowngradeBuy ➝ In-LineLow
12/7/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$178.00Low
12/1/2020UBS GroupDowngradeIn-LineLow
11/25/2020UBS GroupDowngradeBuy ➝ In-LineLow
11/17/2020UBS GroupDowngradeIn-LineLow
11/11/2020UBS GroupDowngradeBuy ➝ In-LineLow
11/5/2020UBS GroupDowngradeIn-LineLow
10/30/2020UBS GroupDowngradeBuy ➝ In-LineLow
10/28/2020Barrington ResearchDowngradeOutperform ➝ UnderperformLow
10/28/2020Robert W. BairdDowngradeOutperform ➝ Neutral$178.00Low
8/10/2020BTIG ResearchDowngradeBuy ➝ NeutralLow
8/6/2020UBS GroupDowngradeBuy ➝ Neutral$150.00 ➝ $177.50Low
8/3/2020Jefferies Financial GroupBoost Price TargetBuy$130.00 ➝ $178.00High
8/3/2020BTIG ResearchBoost Price TargetBuy$133.00 ➝ $177.50High
8/2/2020Piper SandlerDowngradeOverweight ➝ Neutral$142.00 ➝ $177.50High
7/27/2020Piper SandlerBoost Price TargetOverweight$130.00 ➝ $142.00High
5/5/2020UBS GroupLower Price TargetBuy$160.00 ➝ $150.00Medium
5/5/2020Barrington ResearchReiterated RatingBuy$147.00 ➝ $137.00High
5/5/2020Piper SandlerBoost Price TargetOverweight$126.00 ➝ $130.00High
5/4/2020BTIG ResearchReiterated RatingBuy$133.00High
4/19/2020Piper SandlerInitiated CoverageOverweight$126.00High
4/19/2020Evercore ISIDowngradeOutperform ➝ UnderperformHigh
4/17/2020JPMorgan Chase & Co.Lower Price TargetUnderweight$100.00 ➝ $90.00High
4/9/2020Evercore ISIDowngradeOutperform ➝ Underperform$163.00 ➝ $105.00Low
4/7/2020Piper SandlerInitiated CoverageOverweight$126.00High
4/1/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$171.00 ➝ $114.00High
3/10/2020BTIG ResearchLower Price Target$157.00 ➝ $143.00High
3/10/2020Barrington ResearchLower Price Target$160.00 ➝ $147.00High
3/10/2020Robert W. BairdLower Price TargetOutperform$166.00 ➝ $143.00High
3/10/2020UBS GroupLower Price TargetBuy$175.00 ➝ $160.00High
2/12/2020The Goldman Sachs GroupInitiated CoverageBuy$171.00Low
1/30/2020Barrington ResearchReiterated RatingOutperform$152.00 ➝ $160.00Low
1/30/2020Robert W. BairdBoost Price TargetOutperform$158.00 ➝ $166.00Low
1/24/2020BTIG ResearchReiterated RatingBuy$157.00Medium
1/2/2020Evercore ISIUpgradeIn-Line ➝ Outperform$130.00 ➝ $164.00High
12/4/2019UBS GroupBoost Price TargetBuy$155.00 ➝ $160.00High
11/18/2019Robert W. BairdReiterated RatingBuy$158.00Low
10/24/2019Barrington ResearchBoost Price TargetOutperform$146.00 ➝ $152.00High
10/21/2019Barrington ResearchSet Price TargetBuy$146.00High
10/14/2019BTIG ResearchUpgradeNeutral ➝ Buy$130.00Medium
9/23/2019Barrington ResearchBoost Price TargetOutperform$142.00 ➝ $146.00Low
7/26/2019Robert W. BairdSet Price TargetBuy$158.00Low
7/25/2019Barrington ResearchReiterated RatingBuy$142.00Medium
7/24/2019BTIG ResearchReiterated RatingHoldLow
5/2/2019CitigroupLower Price TargetBuy ➝ Buy$174.00 ➝ $165.00Medium
4/25/2019UBS GroupBoost Price TargetBuy ➝ Buy$150.00 ➝ $158.00Medium
4/4/2019Barrington ResearchBoost Price TargetOutperform$135.00 ➝ $150.00Low
3/22/2019Robert W. BairdUpgradeNeutral ➝ Outperform$127.00 ➝ $162.00Low
1/24/2019Barrington ResearchReiterated RatingBuyLow
1/24/2019BTIG ResearchReiterated RatingHoldLow
1/24/2019Royal Bank of CanadaBoost Price TargetSector Perform$130.00Low
1/24/2019Jefferies Financial GroupBoost Price TargetBuy$145.00Low
1/4/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$107.00 ➝ $129.00High
1/2/2019CitigroupLower Price TargetBuy ➝ Buy$145.00 ➝ $131.00Low
11/28/2018UBS GroupInitiated CoverageBuy$140.00High
10/31/2018CitigroupBoost Price TargetBuy ➝ Buy$127.00 ➝ $145.00High
10/24/2018JPMorgan Chase & Co.Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $105.00High
10/19/2018Robert W. BairdInitiated CoverageNeutral ➝ Neutral$119.00Medium
10/4/2018Royal Bank of CanadaSet Price TargetHold$115.00Low
6/28/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$105.00Medium
4/10/2018Royal Bank of CanadaSet Price TargetHold$115.00Low
1/28/2018BTIG ResearchReiterated RatingNeutral ➝ HoldLow
1/25/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$88.00 ➝ $105.00Low
1/25/2018Barrington ResearchUpgradeMarket Perform ➝ Outperform$130.00High
1/25/2018CitigroupBoost Price TargetNeutral ➝ Buy$128.00 ➝ $132.00High
1/25/2018Royal Bank of CanadaBoost Price TargetSector Perform$115.00High
1/25/2018The Goldman Sachs GroupDowngradeNeutral ➝ Sell$98.00High
1/3/2018Evercore ISIInitiated CoverageUnderperform ➝ Underperform$100.00Low
11/30/2017Royal Bank of CanadaSet Price TargetHold$105.00Low
10/30/2017CitigroupBoost Price TargetNeutral$119.00 ➝ $121.00N/A
10/29/2017BTIG ResearchReiterated RatingHoldN/A
9/7/2017BTIG ResearchDowngradeBuy ➝ NeutralMedium
9/1/2017Royal Bank of CanadaReiterated RatingHold$100.00N/A
8/28/2017Robert W. BairdReiterated RatingHold$99.00Low
7/14/2017Robert W. BairdReiterated RatingNeutral$89.00 ➝ $99.00Low
5/17/2017AegisReiterated RatingHold$91.00Low
5/16/2017The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$92.00Low
5/15/2017CitigroupUpgradeNeutral ➝ BuyLow
5/11/2017Jefferies Financial GroupReiterated RatingBuyLow
5/8/2017BTIG ResearchUpgradeNeutral ➝ Buy$106.00High
5/8/2017CitigroupUpgradeNeutral ➝ BuyHigh
4/27/2017Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
4/27/2017Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$82.00 ➝ $90.00High
4/24/2017Off Wall StreetInitiated CoverageSellLow
2/8/2017Jefferies Financial GroupReiterated RatingBuy$102.00 ➝ $88.00N/A
2/6/2017AegisInitiated CoverageHold$85.00N/A
1/27/2017Barrington ResearchBoost Price TargetOutperform$98.00 ➝ $102.00N/A
1/26/2017Evercore ISIDowngradeHold ➝ Sell$81.50N/A
1/23/2017Royal Bank of CanadaSet Price TargetHold$91.00 ➝ $93.00N/A
1/23/2017Royal Bank of CanadaBoost Price TargetSector Perform$91.00 ➝ $93.00N/A
1/23/2017Royal Bank of CanadaReiterated RatingSector Perform$91.00 ➝ $93.00N/A
1/6/2017Royal Bank of CanadaReiterated RatingHoldN/A
12/23/2016Jefferies Financial GroupReiterated RatingBuy$102.00N/A
12/1/2016Jefferies Financial GroupReiterated RatingBuy$102.00N/A
10/31/2016BTIG ResearchReiterated RatingHoldN/A
9/28/2016Jefferies Financial GroupReiterated RatingBuy$98.00N/A
9/28/2016Robert W. BairdBoost Price TargetNeutral$91.00 ➝ $99.00N/A
7/28/2016Barrington ResearchLower Price TargetOutperform$102.00 ➝ $93.00N/A
7/28/2016Morgan StanleyBoost Price TargetUnderweight$80.00 ➝ $86.00N/A
7/28/2016CitigroupBoost Price TargetNeutral$84.00 ➝ $88.00N/A
7/28/2016Brean CapitalBoost Price TargetBuy$87.00 ➝ $90.00N/A
7/28/2016Jefferies Financial GroupBoost Price TargetBuy$95.00 ➝ $98.00N/A
(Data available from 7/25/2016 forward)
Varian Medical Systems logo
Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through Oncology Systems and Proton Solutions segments. The Oncology Systems segment offers hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, artificial intelligence based adaptive radiotherapy, and brachytherapy, as well as quality assurance equipment. Its products include linear accelerators, brachytherapy afterloaders, treatment accessories, and quality assurance software; and information management, treatment planning, image processing, clinical knowledge exchange, patient care management, decision-making support, and practice management software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, physicians' offices, medical oncology practices, radiotherapy centers, and cancer care clinics. The Proton Solutions segment designs, develops, manufactures, sells, and services products and systems for delivering proton therapy for the treatment of cancer. The company has a strategic agreement with McKesson Corp. to supply treatment delivery systems and planning, services, and radiotherapy information system solutions to its U.S. Oncology Network and Vantage Oncology affiliated sites of care; and a strategic partnership with Siemens AG to represent Siemens diagnostic imaging products to radiation oncology clinics in the United States and other select markets. Varian Medical Systems, Inc. was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. The company was founded in 1948 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $177.07
Low: $177.07
High: $177.07

50 Day Range

MA: $177.00
Low: $176.53
High: $177.29

52 Week Range

Now: $177.07
Low: $103.67
High: $177.38

Volume

N/A

Average Volume

746,779 shs

Market Capitalization

$16.26 billion

P/E Ratio

60.43

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Varian Medical Systems?

The following sell-side analysts have issued research reports on Varian Medical Systems in the last year: Barrington Research, BTIG Research, Jefferies Financial Group Inc., Piper Sandler, Robert W. Baird, and UBS Group AG.
View the latest analyst ratings for VAR.

What is the current price target for Varian Medical Systems?

5 Wall Street analysts have set twelve-month price targets for Varian Medical Systems in the last year. Their average twelve-month price target is $177.70, suggesting a possible upside of 0.4%. Robert W. Baird has the highest price target set, predicting VAR will reach $178.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $177.50 for Varian Medical Systems in the next year.
View the latest price targets for VAR.

What is the current consensus analyst rating for Varian Medical Systems?

Varian Medical Systems currently has 1 sell rating and 5 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VAR, but not buy more shares or sell existing shares.
View the latest ratings for VAR.

What other companies compete with Varian Medical Systems?

How do I contact Varian Medical Systems' investor relations team?

Varian Medical Systems' physical mailing address is 3100 Hansen Way, Palo Alto CA, 94304. The medical equipment provider's listed phone number is 650-493-4000 and its investor relations email address is [email protected] The official website for Varian Medical Systems is www.varian.com.